Nurx Works with Gifthealth to Streamline Access to Lilly's Medication Zepbound®
Obesity and overweight affect more than 2 out of 3 women over the age of 20 in the United States and is a risk that increases with age. What's more, 11.5% of women have severe obesity, a higher rate than in men. Overweight and obesity have profound health implications, increasing the risks of cardiovascular disease, type-2 diabetes, certain cancers, and complications during pregnancy. This is why addressing overweight and obesity is crucial for improving women's health overall. However, losing weight and keeping it off can be challenging: studies show that only 1 in 10 adults with overweight and obesity achieve weight loss of 5% or more each year.
Recognizing these challenges, Nurx is committed to providing women with effective, evidence-based weight management solutions. This integration with Gifthealth will streamline access to Zepbound®, an FDA-approved medication for obesity and chronic weight management, for clinically-eligible patients with an on-label prescription from a Nurx-affiliated provider. This integration arrangement also underscores Nurx's dedication to empowering women with the tools and support necessary to achieve their health goals.
As demand for obesity and chronic weight management medications like Zepbound® continues to rise, Nurx is committed to providing comprehensive telehealth care for women navigating weight management. By integrating Gifthealth's pharmacy fulfillment capabilities, Nurx patients will benefit from streamlined access to Zepbound® vials, and can take advantage of Gifthealth's transparent pricing and nationwide delivery — key factors in making obesity care more accessible.
"At Nurx, we believe that every woman deserves access to the healthcare solutions that best fit her needs — including safe and effective weight management medications," said Rajani Rao, Chief Business Officer at Nurx. "This integration agreement with Gifthealth allows us to streamline barriers to access, ensuring women can get the medication they need, and pair it with Nurx's comprehensive approach to weight management, which provides ongoing access to physicians and support in making lifestyle changes."
Gifthealth has been at the forefront of prescription innovation. This new integration agreement with Nurx will help streamline the prescription fulfillment process for weight management treatments, reinforcing both companies' missions to provide affordable, high-quality care. "We are excited to work with providers such as Nurx to streamline access to authentic Zepbound® vials for women nationwide," said Robert Hoppe, EVP of Life Sciences at Gifthealth. "Our goal is to remove cost and logistical barriers to essential medications, and through these integrations, we can help more patients get the care they need."
About Nurx by Thirty MadisonNurx is the leading women's healthcare company making high-quality, judgment-free care accessible and affordable for millions. By removing barriers like cost, stigma, and provider shortages, we provide convenient, personalized treatment across 20+ conditions, including reproductive and sexual health, dermatology, mental health, migraine, hair loss, and weight management. With over 2 million patients served and more than 600,000 actively receiving care, Nurx connects patients directly with trusted healthcare providers and delivers treatment right to their doorstep — ensuring ongoing, specialty-level support that evolves with their needs.
About Thirty Madison Thirty Madison offers end-to-end, high-quality virtual specialized care for patients experiencing a range of conditions. Through its brands — Keeps for men's hair loss, Cove for migraine, and Nurx for women's health — Thirty Madison supports the unique needs of its patients with ongoing access to personalized care and specialty-level telemedicine. Thirty Madison's unique care model delivers care that is accessible, affordable, and focused on improving outcomes. Learn more at ThirtyMadison.com.
About Gifthealth Gifthealth is a digital pharmacy solution founded in 2020, focused on simplifying the prescription process for patients, providers, and manufacturers. By leveraging technology, Gifthealth ensures cost-effective medication access, with a mission to improve adherence and health outcomes. Learn more at gifthealth.com.
Media Contact:Stephanie HallPitch Public Relations480.216.5433 | Stephanie@Pitchpublicrelations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nurx-works-with-gifthealth-to-streamline-access-to-lillys-medication-zepbound-302423940.html
SOURCE Nurx
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
31 minutes ago
- Boston Globe
Whoop there it is: FDA wants to regulate wearable firm's blood pressure tool
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up But in a response sent Aug. 4, Whoop rejected the FDA's assessment, saying the software didn't meet the definition of a medical device and the company would continue to offer the feature to users. The company, which shared the letter with The Boston Globe, also argued the move went against the goals of the Trump administration. Advertisement 'Seeking to regulate the feature as a medical device also runs counter to the stated policy of the Secretary of the Department of Health and Human Services, Robert F. Kennedy Jr., of 'clearing away regulatory barriers so innovation can thrive,'' Whoop said in the letter. Advertisement Whoop's refusal to comply with the FDA's request is uncommon, legal experts said. The FDA, which oversees the safety of medical devices and pharmaceuticals, is usually the ultimate decider of what comes under its jurisdiction and which devices can be sold to help people manage or treat health conditions. Chris Robertson, a Boston University law professor who teaches FDA law, said any communication from the FDA to a company is typically enough to make the company get in line with federal standards. 'You're playing with fire here,' Robertson said. 'That means that Whoop is taking a real calculated gamble.' Wearable technology sits in a grey area when it comes to regulation. The wearables market, estimated by one market intelligence group to be worth $84 billion in 2024, is rapidly expanding, and companies are racing to add new features that give users unique health measurements. Related : Smart wristbands, watches and rings that assess heart rates don't have to get cleared as medical devices. But Whoop competitors, such as Apple and Fitbit, have sought FDA approval for certain software tools in recent years. The crux of Whoop's argument rests on the 21st Century Cures Act, a 2016 law that exempts wellness software features from the definition of a medical device, so long as those features aren't related to the diagnosis, prevention, or treatment of a disease. Blood Pressure Insights, Whoop said, is only intended to be used as a way to gauge a person's performance, quality of sleep, and stress levels . The FDA, however, has rejected Whoop's characterization of the blood pressure tool. In its letter, the agency said the product qualifies as a medical device because its measurements are 'inherently associated with the diagnosis of a disease or condition,' such as hypertension, or high blood pressure. Advertisement Whoop has registered one of its products with the FDA, securing medical device approval for its Heart Screener tool. That tool measures the heart's electrical activity to alert users to potentially abnormal heart rates and atrial fibrillation, a common type of abnormal heart rhythm. The FDA said it doesn't comment on 'ongoing investigations, compliance matters or enforcement activities except with the company involved.' Related : The confrontation is reminiscent of the clash more than a decade ago between the FDA and the personal genomics platform 23andMe, said health law expert Frances Miller, who also teaches at Boston University. The FDA and 23andMe went back and forth on whether the company's health test — which the company claimed could tell customers their risk of conditions like gallstones, heart disease, or arthritis — constituted a medical device. In 2013, the FDA sent a warning letter to 23andMe much like the one it sent Whoop, and 23andMe ultimately capitulated. But the landscape looks different today, Miller said. The FDA has experienced significant cuts under President Trump, and federal agencies as a whole have lost power. In addition, Kennedy has publicly stated his vision that 'every American is wearing a wearable within four years.' Whether Whoop will win its fight against regulation is unclear, Miller said. 'I could have given you a very confident answer a year and a half ago,' Miller said. 'Not now. They're pushing the envelope.' Marin Wolf can be reached at
The Hill
an hour ago
- The Hill
FDA eyes warning label for antidepressants during pregnancy
The Food and Drug Administration (FDA) is considering placing a black-box warning on antidepressant use in pregnancy, alarming some doctors who worry that a reignited debate about the drugs' safety will discourage pregnant people from seeking treatment. FDA Commissioner Marty Makary recently hosted a panel discussion about the use of antidepressants during pregnancy, specifically serotonin reuptake inhibitors (SSRIs), with participants challenging the scientific consensus. While the drugs may pose some risk during pregnancy, the risks associated with not treating mood disorders like depression, to both pregnant people and developing fetuses, are much higher, according to physicians and medical experts. The American College of Obstetricians and Gynecologists (ACOG) released a statement calling the discussion 'alarmingly unbalanced,' warning that it is dangerous to minimize the effects of mental health conditions during pregnancy and postpartum. 'Unfortunately, the many outlandish and unfounded claims made by the panelists regarding SSRIs will only serve to incite fear and cause patients to come to false conclusions that could prevent them from getting the treatment they need,' the statement reads. Many panelists suggested pregnant people should be better warned about the harms the drugs pose to a developing fetus and discussed changing current labeling on antidepressants. Makary said in his opening remarks the drugs could influence the development of organs like the brain and heart in utero. He added that SSRIs have been 'implicated in different studies to be involved in postpartum hemorrhage, pulmonary hypertensions and cognitive downstream effects in the baby.' One of the panelists, Anick Bérard, a professor of epidemiology at the University of Montreal, claimed that the use of the SSRIs paroxetine and fluoxetine greatly increased the risk of adverse health events like miscarriage or low birth weight. For example, Bérard stated that SSRI use during pregnancy increased the absolute risk of miscarriage from about 6 percent to 10 percent. 'This needs to be well talked about when treating pregnant women who are depressed, anxious or using antidepressants,' she said. Physicians and physician groups have since criticized the discussion, calling it 'one-sided' given that only one of the 10 panelists spoke positively about SSRIs and how they can be used as an effective tool to treat depression and anxiety during pregnancy. Tiffany Moore Simas, an OB-GYN at UMass Memorial Health, said the unbalanced nature of the discussion will worsen stigma around antidepressant use during pregnancy and that a 'black box' label is not necessary on the drugs. 'Many perinatal individuals choose not to do pharmacotherapy for fear of fetal harm and for the stigma associated with psychiatric medication,' she said. 'That panel added to this fear of harm.' A spokesperson for the Department of Health and Human Services, which oversees the FDA, would not comment on any future policy decisions regarding antidepressants. The spokesperson did say that suggesting the expert panel was 'one-sided' or politically driven is 'insulting' to its participants. 'Commissioner Makary has an interest in ensuring policies reflect the latest gold standard science and protect public health,' the spokesperson said. 'To suggest that his engagement on women's health signals a desire to manipulate outcomes is politically motivated and undermines the serious work being done to improve care for millions of women.' Many people struggle with their mental health during pregnancy, with research showing that up to 20 percent of women experience depression during a pregnancy, and about 20 percent suffer from anxiety. About 8 percent of these women take an SSRI to treat the conditions. Those conditions carry health risks if left untreated, like preeclampsia, preterm birth, low birth weight, and suicide — one of the leading causes of maternal mortality in the United States. Some research suggests that 5 to 14 percent of pregnant or postpartum people experience suicidal ideation and that suicide could account for 20 percent of postpartum deaths. 'There is a real, biologic reason why pregnant and postpartum persons are susceptible to these conditions, and we need to treat them as needed,' said Moore Simas. 'There are consequences to not doing that.' Recommending that a patient start or stay on an SSRI during pregnancy is not a decision that physicians take lightly, doctors told The Hill, and providers typically will try to limit the number of potentially harmful exposures to a fetus. As a result, the first line of treatment for mild depression and sometimes moderate depression is therapy. But moderate and severe depression are important to treat, and there is 'reassuring' evidence that treating those conditions with SSRIs does not expose pregnant people to increased risks of birth defects, according to Nicole Leistikow, a psychiatry professor at the University of Maryland who specializes in treating women. There is a roughly 3 to 5 percent chance of birth defects occurring in any given pregnancy, according to data from the Centers for Disease Control and Prevention, and numerous large studies conducted over the last 30 years show that SSRIs do not increase this risk. FDA panelists noted that there have not been randomized trials to assess the safety of SSRIs, which some physician groups, like ACOG, agree should be conducted and prioritized. But physicians who spoke with The Hill noted that the studies panelists referenced were not well designed, with some having inappropriate control groups. They added that well-designed studies on antidepressant use in pregnancy will compare outcomes between appropriate groups, like women with depression taking antidepressants and women with depression not taking antidepressants.
Newsweek
2 hours ago
- Newsweek
Cheese Recall Over 'Rodent Activity' Sparks Diarrhea Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A cheese has been recalled due to "rodent activity," with food inspectors urgently warning customers to dispose of the product to prevent risk of illnesses. Quesito El Establo of Salem, New Hampshire, on Tuesday announced the recall of its Spanish Cheese (Quesito Colombiano) manufactured in its facility and sold in Hispanic/Latino retail stores in Massachusetts. The recall affects about 2,100 items, the company told Newsweek. U.S. Food and Drug Administration (FDA) monitors observed "the presence of rodent, rodent activity, and other insanitary conditions during the manufacturing and storage process" during an inspection earlier that day, the company said. Why It Matters The FDA said the presence of rodent activity and other insanitary conditions during manufacturing and storage may have allowed contamination by salmonella, an organism that can cause serious and sometimes fatal infections. The FDA recall notice listed vulnerable groups at greater risk—infants, young children, pregnant women, the elderly and people with weakened immune systems—and described symptoms including fever, diarrhea, nausea, vomiting and abdominal pain. What To Know The company paused production while the agency and the firm investigated. Quesito El Establo told Newsweek via email on Wednesday the company was looking for a new site and hoped to move within three months, subject to regulatory approvals. A spokesperson said the issues raised may have been caused by "seasonal climate conditions and increased pest activity in the surrounding area," and that it had carried out deep cleaning, enhanced pest control measures, upgraded facilities, updated paperwork protocols, and retrained employees. The affected product was described as plastic-wrapped cheese placed in Ziploc bags of approximately 1 pound, featuring a blue sticker with a cow image and the words "Quesito Colombiano" in yellow. The FDA said products with the expiration code "AUG 22 2025" or earlier were included in the recall. The label attached to the packaging of the Spanish Cheese (Quesito Colombiano) being recalled. The label attached to the packaging of the Spanish Cheese (Quesito Colombiano) being recalled. Quesito El Establo/FDA The agency said that no illnesses had been reported to date. Consumers with concerns about possible salmonella symptoms have been advised to seek medical attention, especially if they belonged to high-risk groups. Consumers were advised not to consume the recalled product and to return it to the place of purchase for a full refund. For questions, the company provided a contact number: 617-842-0513, Monday through Saturday, 9 a.m. to 5 p.m. ET. What People Are Saying An Quesito El Establo spokesperson told Newsweek via email on Wednesday: "Following the FDA inspection, observations included the presence of rodents and other unsanitary conditions in certain production and storage areas. "While no laboratory tests have confirmed contamination and no illnesses have been reported, these findings may have been influenced by external factors such as seasonal climate conditions and increased pest activity in the surrounding area. "As a precaution, production was halted immediately, and we have implemented corrective actions including deep cleaning, enhanced pest control measures, facility upgrades, updated SOPs, and employee retraining to ensure the highest food safety standards moving forward." What Happens Next FDA inspectors are expected to carry out an evaluation of the health hazard. Recalls are classified into three categories to indicate the relative degree of risk. They are:
